Isomorphic Labs, Alphabet's AI-driven drug discovery subsidiary, is preparing to launch its first human clinical trials.
The company, spun off from Google DeepMind in 2021, uses AI to design drugs more efficiently, aiming to revolutionize the drug development process.
In March 2025, Isomorphic Labs secured $600 million in funding, led by Thrive Capital. This investment will accelerate the development of their AI drug design engine.
Colin Murdoch, President of Isomorphic Labs, confirmed the imminent start of human trials. Partnerships with Novartis and Eli Lilly are in place to expedite treatment development.
This innovative approach aims to shorten the drug discovery timeline by utilizing AI to predict molecular structures with unprecedented accuracy.
As of July 2025, Isomorphic Labs is on the cusp of launching its first human trials, marking a significant milestone in AI integration in pharmaceutical research.